United States Veterinary Healthcare Market Size and Share

United States Veterinary Healthcare Market (2026 - 2031)
View Global Report

United States Veterinary Healthcare Market Analysis by 麻豆视频

The United States veterinary healthcare market size is projected to expand from USD 21.21 billion in 2025 and USD 22.34 billion in 2026 to USD 28.98 billion by 2031, registering a CAGR of 5.34% between 2026 to 2031. Growth rides on rising pet humanization, productivity pressures in large-scale livestock operations, and a regulatory environment that favors fast-track pathways for innovative therapeutics and diagnostics. Companion-animal owners increasingly accept prices that mirror human healthcare as they seek chronic-disease management, while livestock producers focus on feed-conversion efficiency and zoonotic-risk reduction. The 2024 restructuring of the FDA Center for Veterinary Medicine into discrete companion- and production-animal divisions tightens this focus by aligning review standards with each sub-market鈥檚 economic logic. Competitive advantage hinges on ecosystem lock-in: platform strategies that bind hardware, software, and reference-lab services drive recurring revenue, and artificial intelligence (AI) tools embedded in imaging and molecular platforms narrow the diagnostic gap between primary-care practitioners and specialists. Workforce shortages, biologics supply vulnerabilities, and elongated approval timelines temper growth but also amplify returns for firms able to navigate these hurdles.

Key Report Takeaways

  • By product, therapeutics held 62.46% of United States veterinary healthcare market share in 2025, while diagnostics are on track for the fastest 6.76% CAGR through 2031.  
  • By animal type, dogs and cats contributed 49.26% of 2025 revenue, whereas poultry is forecast to advance at a 6.67% CAGR to 2031, reflecting biosecurity investment after 2024 HPAI outbreaks.  
  • By end user, veterinary clinics captured 47.89% share in 2025, yet reference laboratories are poised for a 6.81% CAGR through 2031, supported by consolidation and next-generation sequencing roll-outs.

Note: Market size and forecast figures in this report are generated using 麻豆视频鈥檚 proprietary estimation framework, updated with the latest available data and insights as of January 2026.

Segment Analysis

By Product: Diagnostics Outpace Therapeutics Growth

Diagnostics revenue is projected to climb at a 6.76% CAGR through 2031, surpassing therapeutics and lifting the United States veterinary healthcare market size for this segment to USD 11.2 billion by the end of the forecast period. Therapeutics retained a 62.46% share in 2025, but information-rich point-of-care assays now compress diagnostic cycles to minutes, compelling practices to preface treatment with evidence rather than empirical protocols. The United States veterinary healthcare market share advantage for therapeutics is therefore narrowing as diagnostics command a larger share of the clinical workflow.

Vaccines and parasiticides dominate companion-animal spending, while feed additives and anti-infectives drive production-animal uptake. Zoetis鈥檚 Simparica Trio reduced owner pill burden and captured incremental share, whereas monoclonal antibodies such as Librela inaugurate recurring injection models. Catalyst One and ProCyte One analyzers yield full blood work within 10 minutes, delivering lab-grade accuracy chairside. As AI augments imaging reads, general practitioners confidently perform advanced diagnostics without specialist referrals, deepening in-house revenue capture and cementing platform loyalty.

United States Veterinary Healthcare Market: Market Share by Product

By Animal Type: Companion Animals Lead as Poultry Accelerates

Dogs and cats delivered 49.26% of 2025 revenue, anchoring the United States veterinary healthcare market size for companion animals at USD 11.0 billion. Poultry, though smaller in absolute terms, is projected for a 6.67% CAGR, the swiftest among livestock groups, driven by biosecurity investments that defend integrated supply chains against HPAI shocks. The United States veterinary healthcare market share for poultry therapeutics and diagnostics will therefore expand by more than 100 basis points by 2031.

Companion-animal owners fund advanced oncology, orthopedic, and cardiology services that parallel human care pathways. In poultry and swine, vertical integrators deploy predictive analytics and rapid diagnostics to safeguard throughput. Gene-edited pigs resistant to PRRS await commercialization once trade barriers resolve, while ruminant segments adapt to antimicrobial-use restrictions that elevate veterinarian oversight and shift purchasing authority. Equine spending concentrates in performance horses where regenerative therapies command price premiums despite limited clinical evidence.

By End User: Reference Laboratories Capture Growth

Reference laboratories are on track for a 6.81% CAGR to 2031, elevating their portion of United States veterinary healthcare market revenue as centralized platforms amortize high-throughput sequencing and mass spectrometry across millions of tests. Veterinary clinics still hold 47.89% share as of 2025, but capacity constraints in imaging and molecular tests push complex cases to labs that guarantee sensitivity and specificity levels unattainable in-house.

Corporate chains funnel samples to captive labs, tightening lock-in while small independent clinics leverage subscription models that bundle equipment leases with reagent contracts. Livestock producers buy through integrator contracts prioritizing cost per pound gained, encouraging pharmaceutical firms to append consulting and data-analytics services to product bids. Home-care and tele-veterinary users emerged after 2024 regulatory relaxations allowed remote prescribing, with Chewy鈥檚 subscription model undercutting traditional advice channels and widening the market鈥檚 digital front door.

United States Veterinary Healthcare Market: Market Share by End User
United States Veterinary Healthcare Market: Market Share by End User

Geography Analysis

The southern United States hosts dense poultry and swine operations that amplify disease-spread risk and spur early adoption of on-farm diagnostics and biosecurity hardware, positioning the region as the growth engine for the United States veterinary healthcare market. Midwestern corridors where beef and dairy cattle dominate exhibit steady demand tied to Veterinary Feed Directive compliance, driving purchases of antimicrobial alternatives and herd-health analytics. The Northeast and West Coast record the nation鈥檚 highest per-pet household spending, underpinned by affluent urban centers where pet health mirrors human wellness trends.

Corporate veterinary chains concentrate clinics in coastal metros, funneling high volumes of samples to centralized labs and accelerating AI algorithm refinement. Rural western states face acute workforce shortages that curb service penetration despite sizable livestock inventories. Telemedicine adoption partially bridges this gap, but connectivity barriers persist in sparsely populated counties. The presence of major veterinary schools in the Midwest fosters translational research partnerships that pilot novel gene-edited livestock and precision dairy platforms. Climate variability in the Southwest influences vector-borne disease patterns, increasing demand for year-round parasiticides.

Regulatory initiatives such as state-level telehealth legislation diffuse fastest in western states with vast catchment areas, driving experimentation in hybrid care models. Federal surveillance efforts headquartered in Iowa and Georgia channel funding toward local contract laboratories, seeding new reference capacities that later scale nationally. Across regions, pet insurance enrollment rises fastest in metros with large millennial populations, reflecting digital-first product distribution and employer-sponsored benefit adoption. Collectively, these regional dynamics diversify revenue drivers while sustaining the unified growth trajectory of the United States veterinary healthcare market.

Regulatory Landscape

The United States veterinary healthcare market operates under a dual federal framework led by the FDA Center for Veterinary Medicine (CVM) for animal drug safety, efficacy, and manufacturing quality (Federal Food, Drug, and Cosmetic Act) and USDA APHIS for animal welfare, interstate movement, and disease control requirements embedded in 9 CFR. Recent administrative and rulemaking actions point to continued oversight across drug approvals and compliance: in April 2026, the FDA amended animal drug regulations to reflect application-related actions (including NADA, ANADA, and CNADA), adding procedural clarity that affects labeling, lifecycle maintenance, and sponsor compliance activities.

Food-animal policy continues to tighten around stewardship and traceability. In February 2026, CVM issued guidance to sponsors on defining durations of use for medically important antimicrobial drugs in food-producing animals, increasing the documentation burden for typical and maximum duration ranges and supporting Veterinary Feed Directive-era practices. On the livestock traceability side, USDA APHIS implemented animal disease traceability requirements in November 2024 for eartags applied for interstate movement of cattle and bison to be both visually and electronically readable, reinforcing demand for compliant identification, recordkeeping, and veterinarian-supported herd health programs.

Competitive Landscape

Zoetis remains the largest single player, leveraging cross-category bundling to deepen account penetration, while IDEXX dominates diagnostics with a 60% stake anchored in its integrated hardware-software-lab ecosystem. Boehringer Ingelheim amplifies parasiticide production capacity with a USD 150 million Georgia plant expansion that fortifies supply security. Elanco鈥檚 microbiome analytics acquisition reinforces a pivot toward precision livestock offerings that embed data services into product packages.

Platform lock-in rather than price competition defines strategic positioning. IDEXX鈥檚 AI interpretation tools prompt automatic treatment pathways that incline clinicians toward its reagents. Zoetis extends its Petcare Rewards program to rebate diagnostics when paired with Simparica Trio, elevating lifetime customer value and thwarting generic encroachment. Mars Veterinary Health integrates Banfield clinics with Antech labs, capturing margin at multiple value-chain nodes and standardizing practice protocols across 3,000 locations.

Disruptors arise from adjacent segments. Pumpkin Insurance complements policies with embedded virtual visits, vertically integrating risk management and care delivery. Chewy鈥檚 telehealth subscription commoditizes basic consultations, siphoning low-complexity cases from brick-and-mortar clinics. Patent cliffs looming for blockbuster parasiticides between 2027 and 2029 may compress margins for incumbents, redirecting R&D spend toward biologics and gene therapies with durable exclusivity. Start-ups targeting niche segments such as aquaculture therapeutics exploit regulatory pathways left unserved by large firms, fragmenting the market at the edges while core categories remain consolidated.

United States Veterinary Healthcare Industry Leaders

  1. Elanco Animal Health

  2. Merck & Co. Inc.

  3. Idexx Laboratories

  4. Zoetis, Inc.

  5. Boehringer Ingelheim International GmbH

  6. *Disclaimer: Major Players sorted in no particular order
United States Veterinary Healthcare Market Concentration

Market Opportunities and Future Outlook

Diagnostics-led workflow changes create whitespace for platforms that combine advanced testing with clinic efficiency tools and integrated interpretation. In 2026, MiDOG Animal Diagnostics launched expanded sequencing-based services, including an enhanced Whole Genome Sequencing offering (March 2026) and a dedicated NGS-based parasite detection test (July 2026). These launches highlight commercialization momentum for genomics in routine veterinary decision-making and for antimicrobial resistance profiling. Zoetis also announced an agreement to acquire VitalRADS to expand its Virtual Reference Laboratory, signaling continued strategic interest in teleradiology and AI-assisted workflows that connect general practices to specialist-grade reads without increasing local specialist capacity.

On the therapeutics side, regulatory emphasis on antimicrobial stewardship (CVM guidance finalized in February 2026 on durations of use for medically important antimicrobials in food animals) increases the value of evidence-backed labels, compliance support, and data services attached to product portfolios, particularly for production-animal customers. At the point of care, rising veterinary service costs (noted as 7.4% year-over-year as of January 2026 in industry commentary) intensify demand for lower-friction preventive and at-home solutions, along with AI-driven operational tools (such as AI scribing and AI-assisted cytology) that improve clinic throughput and margins. Together, these shifts support opportunities for vendors that bundle diagnostics, tele-enabled interpretation, and subscription-style consumables into predictable practice economics while meeting evolving stewardship and traceability requirements.

Recent Industry Developments

  • July 2026: Zoetis received European Commission marketing authorization for Poulvac Procerta HVT-ND, expanding its poultry biologics portfolio with a regulated vaccine pathway. The authorization strengthens multinational supply and registration positioning for poultry disease prevention programs that are increasingly tied to integrator biosecurity and continuity-of-supply requirements.
  • February 2026: MSD Animal Health (Merck & Co., Inc.) reported FDA approval of NUMELVI (atinvicitinib tablets) for the control of pruritus associated with allergic dermatitis in dogs. The approval adds a new branded option in a high-frequency companion-animal dermatology category, where chronic management supports recurring pharmacy and clinic revenue.
  • December 2025: MSD Animal Health announced conditional FDA approval for EXZOLT (fluralaner) 5% pour-on for cattle for New World screwworm (Cochliomyia hominivorax) larvae (myiasis). This action broadened the toolkit for livestock parasite control under regulatory mechanisms designed to address urgent animal health threats and protect production continuity.

Table of Contents for United States Veterinary Healthcare Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising pet ownership & expenditure
    • 4.2.2 Advanced technology & innovation in animal healthcare
    • 4.2.3 Government & animal-welfare initiatives
    • 4.2.4 Productivity pressures increasing zoonotic risk
    • 4.2.5 AI-driven predictive diagnostics adoption
    • 4.2.6 Gene-edited therapeutics pipeline momentum
  • 4.3 Market Restraints
    • 4.3.1 High costs of veterinary testing & treatment
    • 4.3.2 Stringent regulatory approval timelines
    • 4.3.3 Veterinary workforce shortage
    • 4.3.4 Biologics-input supply-chain vulnerabilities
  • 4.4 Supply / Value-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter鈥檚 Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Buyers/Consumers
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Threat of Substitute Products
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Product
    • 5.1.1 Therapeutics
    • 5.1.1.1 Vaccines
    • 5.1.1.2 Parasiticides
    • 5.1.1.3 Anti-infectives
    • 5.1.1.4 Medical Feed Additives
    • 5.1.1.5 Other Therapeutics
    • 5.1.2 Diagnostics
    • 5.1.2.1 Immunodiagnostic Tests
    • 5.1.2.2 Molecular Diagnostics
    • 5.1.2.3 Diagnostic Imaging
    • 5.1.2.4 Clinical Chemistry
    • 5.1.2.5 Other Diagnostics
  • 5.2 By Animal Type
    • 5.2.1 Dogs and Cats
    • 5.2.2 Horses
    • 5.2.3 Ruminants
    • 5.2.4 Swine
    • 5.2.5 Poultry
    • 5.2.6 Other Animals
  • 5.3 By End User
    • 5.3.1 Veterinary Clinics
    • 5.3.2 Veterinary Hospitals
    • 5.3.3 Reference Laboratories
    • 5.3.4 Livestock Producers
    • 5.3.5 Home-care / Tele-veterinary Users
    • 5.3.6 Others

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Bimeda Inc.
    • 6.3.2 Boehringer Ingelheim Animal Health
    • 6.3.3 Central Garden & Pet (Animal Health)
    • 6.3.4 Ceva Sant茅 Animale
    • 6.3.5 Covetrus
    • 6.3.6 Dechra Pharmaceuticals
    • 6.3.7 Elanco Animal Health
    • 6.3.8 Heska Corporation
    • 6.3.9 IDEXX Laboratories
    • 6.3.10 Mars Veterinary Health
    • 6.3.11 MedVet
    • 6.3.12 Merck Animal Health
    • 6.3.13 Neogen Corporation
    • 6.3.14 Norbrook Laboratories
    • 6.3.15 Patterson Companies (Animal Health)
    • 6.3.16 Phibro Animal Health
    • 6.3.17 Vetoquinol
    • 6.3.18 Virbac SA
    • 6.3.19 Zoetis Inc.

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment

Research Methodology Framework and Report Scope

Market Definition and Coverage

For this study, the United States veterinary healthcare market is defined as spending tied to animal disease prevention, diagnosis, and treatment delivered through veterinary products and diagnostic solutions used across companion and farm animals.

Scope exclusions: Human healthcare, general pet food and grooming, and non-medical boarding or training are not counted in this market sizing.

Segmentation Overview

  • By Product
    • Therapeutics
      • Vaccines
      • Parasiticides
      • Anti-infectives
      • Medical Feed Additives
      • Other Therapeutics
    • Diagnostics
      • Immunodiagnostic Tests
      • Molecular Diagnostics
      • Diagnostic Imaging
      • Clinical Chemistry
      • Other Diagnostics
  • By Animal Type
    • Dogs and Cats
    • Horses
    • Ruminants
    • Swine
    • Poultry
    • Other Animals
  • By End User
    • Veterinary Clinics
    • Veterinary Hospitals
    • Reference Laboratories
    • Livestock Producers
    • Home-care / Tele-veterinary Users
    • Others

Data Sources, Market Sizing, and Validation

Desk Research

Desk research was used to set the demand context and the math guardrails before we finalized the market model. We referenced public, non-paywalled sources such as the US FDA Center for Veterinary Medicine for policy and approval cadence signals, USDA publications for livestock and poultry population trends, and the US Census Bureau for macro spending and price indicators that influence clinic and farm purchasing.

To avoid building the model only from a single angle, we also reviewed sources such as AVMA benchmarks and insights, peer-reviewed veterinary journals for diagnosis and treatment patterns, and company filings plus investor presentations for product mix and category growth commentary. In addition, paid subscriptions for company financials and news intelligence, plus a patent database, were used to cross-check corporate activity and innovation direction where public disclosure was limited. These examples are not exhaustive, and many other sources were used to collect data, validate assumptions, and clarify open questions during research.

Primary Interviews and Surveys

Primary interviews and structured surveys were run with veterinary clinic and hospital stakeholders, reference lab participants, distributors, and domain specialists who track animal health usage in the United States. Inputs were used to confirm what gets purchased in routine care versus specialty care, sense-check the pricing direction for key care pathways, and pressure-test adoption assumptions for diagnostics and therapeutics across companion and production animals.

Distribution of primary research fieldwork respondents

Company typeRespondent positionRegion
Top tier: 32% CXOs: 12%
Mid tier: 53% Functional/Unit leaders: 29%
Smaller Players: 15% Managers: 59%

Market-Sizing & Forecasting

Sizing was built using a top-down approach, where the demand pool was reconstructed from animal populations and care utilization, and then translated into value using price and mix assumptions for diagnostics and therapeutics. To keep totals realistic, selective bottom-up approximations were also used, such as sampled price per test or treatment multiplied by estimated procedure volumes, and channel checks with clinics, labs, and distributors.

Inputs were kept practical and repeatable, so the model leaned on variables such as companion animal visit frequency, diagnostic test adoption in clinics versus reference labs, vaccination and parasite control compliance trends, livestock and poultry herd and flock counts, and observed price movement for common treatment bundles. When a data gap appeared, for example around emerging testing workflows or newer treatment protocols, assumptions were filled using expert ranges and then tightened by comparing them with adjacent indicators that move in the same direction.

For forecasting, scenario analysis was used so the outlook could reflect different paths for clinic capacity, pet owner spending behavior, and preventive care uptake. The final forecast line was selected after reconciling scenario outputs with what primary respondents described as the most likely pricing and volume progression over the next few years.

Data Validation & Update Cycle

Validation was done through several checks that look for mismatches across the model, the input assumptions, and real-world demand signals. Outputs were compared against independent indicators such as animal population trends, clinic visit and workload direction, and observed pricing movement, and then reviewed again when any step produced an outlier result.

Before sign-off, the work is reviewed in multiple passes so category totals reconcile back to the defined scope and the timeline logic stays consistent. Reports are refreshed annually, and interim updates are triggered when material events occur, such as major regulatory shifts or sudden pricing changes that can alter the near-term value trend. Right before delivery, a fresh analyst pass is completed so clients receive the latest updated view.

麻豆视频's United States Veterinary Healthcare Market Market Size Compared With Other Published Estimates

Published market sizes for US veterinary care often do not match because each publisher draws the line around what counts as healthcare and which spending streams are included. Differences also show up when one estimate leans more toward products like therapeutics and diagnostics, while another is closer to clinical service revenue.

The gap usually becomes clearer when refresh timing, currency timing, and the way average selling prices are rolled forward are checked step by step. A model that revalidates pricing and utilization assumptions after a new year of clinic and lab feedback, and then locks the year-average USD conversion for comparability, can land at a different level than estimates that keep older price points or mix shares. That refresh-led difference is reflected in how 麻豆视频 updates its inputs.

Benchmark comparison

SourceMarket SizeGaps in Research Methodology
麻豆视频 USD 21.21 B (2025)
Global Consultancy A USD 38.23 B (2025)This figure is for veterinary services, which typically counts clinic and hospital service revenue more fully, and can also include non-medical service elements that sit outside product-led veterinary healthcare.
Trade Journal B USD 36.52 B (2024)This estimate is anchored to a services-only scope and uses a different base year, so it captures a larger care delivery spend pool and reflects a separate price and utilization cycle than a products plus diagnostics definition.

Taken together, the spread is mostly explained by scope boundaries and timing choices, rather than a simple arithmetic disagreement. By keeping inclusions tied to diagnostics and therapeutics within veterinary healthcare, and by rechecking price and mix assumptions during each refresh, the resulting number stays traceable to clear variables and repeatable steps.

Key Questions Answered in the Report

What is the current valuation of the United States veterinary healthcare market?

The market is valued at USD 22.34 billion in 2026, with forecasts pointing to USD 28.98 billion by 2031.

How fast is the market expected to grow through 2031?

It is projected to register a 5.34% CAGR through the forecast period.

Which product category shows the fastest growth?

Diagnostics are set to grow at a 6.76% CAGR, outpacing therapeutics.

Why is poultry the fastest-growing animal segment?

Biosecurity investments after the 2024 HPAI outbreaks are driving poultry to a 6.67% CAGR.

Which end-user segment is gaining share fastest?

Reference laboratories will expand at a 6.81% CAGR thanks to centralized high-throughput testing.

What key restraint could limit market expansion?

Rising treatment costs, which outpace general inflation, could dampen demand, especially in lower-income areas.

Page last updated on:

United States Veterinary Healthcare Market Report Snapshots